Wall Street analysts expect Rockwell Medical Inc (NASDAQ:RMTI) to post earnings of ($0.12) per share for the current quarter, Zacks reports. Two analysts have made estimates for Rockwell Medical’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.12). Rockwell Medical reported earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 20%. The firm is expected to report its next earnings results on Thursday, March 12th.

On average, analysts expect that Rockwell Medical will report full year earnings of ($0.57) per share for the current financial year, with EPS estimates ranging from ($0.59) to ($0.56). For the next fiscal year, analysts forecast that the business will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.44) to ($0.20). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Rockwell Medical.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Monday, November 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. Rockwell Medical had a negative net margin of 57.77% and a negative return on equity of 139.38%. The company had revenue of $15.41 million during the quarter, compared to analysts’ expectations of $15.40 million.

Several research firms have weighed in on RMTI. Piper Jaffray Companies decreased their target price on shares of Rockwell Medical from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Rockwell Medical in a report on Monday, December 2nd. Finally, Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $9.33.

NASDAQ RMTI traded down $0.07 during trading hours on Friday, hitting $2.72. 24,744 shares of the company’s stock traded hands, compared to its average volume of 293,880. Rockwell Medical has a 52-week low of $1.81 and a 52-week high of $6.88. The company has a market capitalization of $148.38 million, a PE ratio of -5.94 and a beta of 1.49. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.27 and a quick ratio of 2.98. The firm’s 50-day moving average is $2.32 and its 200-day moving average is $2.54.

A number of large investors have recently bought and sold shares of RMTI. Marshall Wace LLP purchased a new stake in shares of Rockwell Medical in the 1st quarter valued at approximately $57,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Rockwell Medical in the 1st quarter valued at about $106,000. Envestnet Asset Management Inc. increased its holdings in shares of Rockwell Medical by 139.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 27,302 shares of the company’s stock valued at $82,000 after purchasing an additional 15,910 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Rockwell Medical by 238.4% in the 2nd quarter. Wells Fargo & Company MN now owns 119,761 shares of the company’s stock valued at $360,000 after purchasing an additional 84,367 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Rockwell Medical by 21.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 129,097 shares of the company’s stock valued at $389,000 after purchasing an additional 22,445 shares during the period. Institutional investors own 21.20% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.

Featured Story: What is the significance of the death cross?

Get a free copy of the Zacks research report on Rockwell Medical (RMTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.